Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022

PD-1 and PD-L1 Inhibitors: Will They Dominate O...

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed ce...

Dec 02, 2022

pd-and-pd-l1-inhibitors-in-cancer-treatment
MedTech News Updates for AnchorDx, UroMems, NeuroLogica, Ypsomed
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States.  The UriFind® bladder cancer assay clinical trial in the U...

Find More
Antibody Drug Conjugates for Cancer Treatment in Asia Healthcare Market
Antibody-Drug Conjugate: The Smart Biological Bomb

Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...

Find More
EGFR-NSCLC Treatment Market Dynamics
Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 230K new cases were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year, accounting for almost 130K deaths. As per DelveIn...

Find More
EGFR and ALK mutations in the East Asian Lung Cancer Market
ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market

Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...

Find More

Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...

Find More

emerging-rna-interference-drugs
RNA Interference: New Class of Drugs In The Fight Against Disease

RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...

Find More

gene-therapy-for-complex-diseases
Gene Therapy: The Next Milestone in Treating Complex Diseases

Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy w...

Find More

Pharma News for Genentech, Sanofi, Merck
Genentech’s gantenerumab Fails in Phase III Trial; CHMP Recommends’ Dupixent; FDA Clears Imfinzi and Imjudo with chemotherapy; NICE Recommends Ipsen’s Cabometyx (cabozantinib); NICE Backs KEYTRUDA; NRG Announces £16 Million Series A Funding; FDA Backs AstraZeneca’s PT027

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Find More

Non-Small Cell Lung Cancer Treatment Market Outlook
Novel Insights Into The Non-Small Cell Lung Cancer Market

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. As per the American Cancer Society, almost 230K new cases were diagnosed in 2022 alone, and almost 130K deaths from lung cancer were recorded in the same year.  Studies show that non-small cel...

Find More

Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More
Toll-like receptors (TLR) 7 and 8 Agonist
Toll-like receptors (TLR)...

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More
Gene Therapies
Gene Therapies

Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....

Find More